Disease on EC 2.7.8.27 - sphingomyelin synthase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Acquired Immunodeficiency Syndrome
Current status and perspectives in ceramide-targeting molecular medicine.
Alzheimer Disease
Current status and perspectives in ceramide-targeting molecular medicine.
Alzheimer Disease
Inhibition of sphingomyelin synthase 1 ameliorates alzheimer-like pathology in APP/PS1 transgenic mice through promoting lysosomal degradation of BACE1.
Asthma
Ceramide/sphingosine-1-phosphate imbalance is associated with distinct inflammatory phenotypes of uncontrolled asthma.
Atherosclerosis
Discovery of 4-Benzyloxybenzo[ d]isoxazole-3-amine Derivatives as Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors that Reduce Chronic Inflammation in db/ db Mice.
Atherosclerosis
Discovery of the selective sphingomyelin synthase 2 inhibitors with the novel structure of oxazolopyridine.
Atherosclerosis
Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor.
Atherosclerosis
Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors.
Atherosclerosis
Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice.
Atherosclerosis
Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice.
Atherosclerosis
Pharmacologic inhibition of sphingomyelin synthase (SMS) activity reduces apolipoprotein-B secretion from hepatocytes and attenuates endotoxin-mediated macrophage inflammation.
Atherosclerosis
Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell.
Atherosclerosis
Sphingomyelin synthase 1 enhances BCR signaling to promote lupus-like autoimmune response.
Atherosclerosis
Sphingomyelin synthase 2 over-expression induces expression of aortic inflammatory biomarkers and decreases circulating EPCs in ApoE KO mice.
Atherosclerosis
[Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice.]
Bacterial Infections
Current status and perspectives in ceramide-targeting molecular medicine.
Breast Neoplasms
Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin.
Carcinogenesis
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Carcinoma
LncRNA THAP9-AS1 accelerates cell growth of esophageal squamous cell carcinoma through sponging miR-335-5p to regulate SGMS2.
Carcinoma, Hepatocellular
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Cardiomyopathies
HILIC-MS-based metabolomics reveal that Astragalus polysaccharide alleviates doxorubicin-induced cardiomyopathy by regulating sphingolipid and glycerophospholipid homeostasis.
Colitis-Associated Neoplasms
Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis-associated colon cancer.
Coronary Disease
[Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice.]
Dermatitis, Atopic
Current status and perspectives in ceramide-targeting molecular medicine.
Diabetes Mellitus
Current status and perspectives in ceramide-targeting molecular medicine.
Diabetes Mellitus
Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAM-1 reduction.
Diabetes Mellitus, Type 2
Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetes.
Encephalitis, Japanese
Sphingomyelin generated by sphingomyelin synthase 1 is involved in attachment and infection with Japanese encephalitis virus.
Esophageal Squamous Cell Carcinoma
LncRNA THAP9-AS1 accelerates cell growth of esophageal squamous cell carcinoma through sponging miR-335-5p to regulate SGMS2.
Fatty Liver
Discovery of 4-Benzyloxybenzo[ d]isoxazole-3-amine Derivatives as Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors that Reduce Chronic Inflammation in db/ db Mice.
Fatty Liver
Imaging Mass Spectrometry Reveals Acyl-Chain- and Region-Specific Sphingolipid Metabolism in the Kidneys of Sphingomyelin Synthase 2-Deficient Mice.
Fatty Liver
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis.
Fatty Liver
Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor ?2 suppression.
Glioma
Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy.
Hepatitis
CD4+ T-cell dysfunctions through the impaired lipid rafts ameliorate concanavalin A-induced hepatitis in sphingomyelin synthase 1-knockout mice.
Hepatitis
Sphingomyelin synthase 1 enhances BCR signaling to promote lupus-like autoimmune response.
Infarction, Middle Cerebral Artery
Protection by D609 Through Cell-Cycle Regulation After Stroke.
Infections
A Genome-Wide CRISPR/Cas9 Screen Reveals the Requirement of Host Sphingomyelin Synthase 1 for Infection with Pseudorabies Virus Mutant gD-Pass.
Infections
Sphingomyelin generated by sphingomyelin synthase 1 is involved in attachment and infection with Japanese encephalitis virus.
Insulin Resistance
A selective sphingomyelin synthase 2 inhibitor ameliorates diet induced insulin resistance via the IRS-1/Akt/GSK-3? signaling pathway.
Insulin Resistance
Characterization of the role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice.
Insulin Resistance
Discovery of 4-Benzyloxybenzo[ d]isoxazole-3-amine Derivatives as Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors that Reduce Chronic Inflammation in db/ db Mice.
Insulin Resistance
Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, Fatty liver, and type 2 diabetes.
Insulin Resistance
GPRC5B-Mediated Sphingomyelin Synthase 2 Phosphorylation Plays a Critical Role in Insulin Resistance.
Leukemia
Ceramide generation during curcumin-induced apoptosis is controlled by crosstalk among Bcl-2, Bcl-xL, caspases and glutathione.
Leukemia
MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
Leukemia
Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia.
Leukemia
Prodrug modification increases potassium tricyclo[5.2.1.0(2,6)]-decan-8-yl dithiocarbonate (D609) chemical stability and cytotoxicity against U937 leukemia cells.
Leukemia
Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.
Liver Diseases
Imaging Mass Spectrometry Reveals Acyl-Chain- and Region-Specific Sphingolipid Metabolism in the Kidneys of Sphingomyelin Synthase 2-Deficient Mice.
Lymphoma
Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAM-1 reduction.
Lymphoma
Phosphoinositide phosphatase SHIP-1 regulates apoptosis induced by edelfosine, Fas ligation and DNA damage in mouse lymphoma cells.
Magnesium Deficiency
Short-term magnesium deficiency upregulates sphingomyelin synthase and p53 in cardiovascular tissues and cells : relevance to de novo synthesis of ceramide.
Malaria
Neutral sphingomyelinase activity dependent on Mg2+ and anionic phospholipids in the intraerythrocytic malaria parasite Plasmodium falciparum.
Malaria
Plasmodium falciparum exports the Golgi marker sphingomyelin synthase into a tubovesicular network in the cytoplasm of mature erythrocytes.
Melanoma
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.
Metabolic Diseases
Discovery of 1,8-naphthyridin-2-one derivative as a potent and selective sphingomyelin synthase 2 inhibitor.
Neoplasm Metastasis
Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin.
Neoplasms
Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy.
Neoplasms
Discovery of 4-Benzyloxybenzo[ d]isoxazole-3-amine Derivatives as Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors that Reduce Chronic Inflammation in db/ db Mice.
Neoplasms
Identification and functional analysis of the risk microRNAs associated with cerebral low-grade glioma prognosis.
Neoplasms
LC-HRMS based approach to identify novel sphingolipid biomarkers in breast cancer patients.
Neoplasms
Measurement of ceramide and sphingolipid metabolism in tumors: potential modulation of chemotherapy.
Neoplasms
MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
Neoplasms
Normalization of sphingomyelin levels by 2-hydroxyoleic acid induces autophagic cell death of SF767 cancer cells.
Neoplasms
Sphingomyelin synthase 2 but not sphingomyelin synthase 1 is upregulated in ovarian cancer and involved in migration, growth and survival via different mechanisms.
Neoplasms
Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
Neoplasms
Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin.
Neoplasms
Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells.
Neoplasms
The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration-from cell and animal models to human disorders.
Neoplasms
The sustained activation of sphingomyelin synthase by 2-hydroxyoleic acid induces sphingolipidosis in tumor cells.
Neoplasms
[Expression of sphingomyelin synthase 1 (SGMS1) gene varies in human lung and oesophagus cancer].
Obesity
Characterization of the role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice.
Obesity
Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAM-1 reduction.
Obesity
Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, Fatty liver, and type 2 diabetes.
Obesity
Malabaricone C as Natural Sphingomyelin Synthase Inhibitor against Diet-Induced Obesity and Its Lipid Metabolism in Mice.
Obesity
Sphingomyelin synthase 2 loss suppresses steatosis but exacerbates fibrosis in the liver of mice fed with choline-deficient, L-amino acid-defined, high-fat diet.
Osteoporosis
A Novel IFITM5 Variant Associated with Phenotype of Osteoporosis with Calvarial Doughnut Lesions: A Case Report.
Osteoporosis
Musculoskeletal phenotype in two unrelated individuals with a recurrent nonsense variant in SGMS2.
Ovarian Neoplasms
Sphingomyelin synthase 2 but not sphingomyelin synthase 1 is upregulated in ovarian cancer and involved in migration, growth and survival via different mechanisms.
Pseudorabies
A Genome-Wide CRISPR/Cas9 Screen Reveals the Requirement of Host Sphingomyelin Synthase 1 for Infection with Pseudorabies Virus Mutant gD-Pass.
Pulmonary Disease, Chronic Obstructive
Airway Resistance Caused by Sphingomyelin Synthase 2 Insufficiency in Response to Cigarette Smoke.
Reperfusion Injury
Sphingomyelin Synthase 2 Inhibition Ameliorates Cerebral Ischemic Reperfusion Injury Through Reducing the Recruitment of Toll-Like Receptor 4 to Lipid Rafts.
Sarcoma
Quantifying Fluorescently Labeled Ceramide Levels in Human Sarcoma Cell Lines in Response to a Sphingomyelin Synthase Inhibitor.
Sphingolipidoses
The sustained activation of sphingomyelin synthase by 2-hydroxyoleic acid induces sphingolipidosis in tumor cells.
sphingomyelin synthase deficiency
A novel mechanism of thrombocytopenia by PS exposure through TMEM16F in sphingomyelin synthase 1 deficiency.
sphingomyelin synthase deficiency
Effect of liver total sphingomyelin synthase deficiency on plasma lipid metabolism.
sphingomyelin synthase deficiency
Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice.
sphingomyelin synthase deficiency
Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice.
sphingomyelin synthase deficiency
Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation.
sphingomyelin synthase deficiency
Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis-associated colon cancer.
sphingomyelin synthase deficiency
[Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice.]
Thrombocytopenia
A novel mechanism of thrombocytopenia by PS exposure through TMEM16F in sphingomyelin synthase 1 deficiency.
Triple Negative Breast Neoplasms
Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
Virus Diseases
Enzyme distributions in subcellular fractions of BHK cells infected with Semliki forest virus: evidence for a major fraction of sphingomyelin synthase in the trans-golgi network.
html completed